Metraipolis › archive › dc_7fef38f3af3d

Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in… — Europe PMC PMID:37725629

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/37725629
DOI
10.1371/journal.pone.0291361
License (as archived)
CC0-1.0
Archived
2026-10-07T12:26:44.033Z
SHA-256 of the archived text
d40d86308faf274af009511bac5e1f84e1dadfde792267d18b8e40ed19d77ff7
Stable URL of this page
https://metraipolis.com/documento/dc_7fef38f3af3d

How to cite

Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in… — Europe PMC PMID:37725629 — Europe PMC (en), https://europepmc.org/article/MED/37725629 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7fef38f3af3d (Metraipolis archive dc_7fef38f3af3d, sha256 d40d86308faf274af009511bac5e1f84e1dadfde792267d18b8e40ed19d77ff7)
BibTeX
@misc{dc7fef38f3af3d,
  title = {Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in… — Europe PMC PMID:37725629},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37725629},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7fef38f3af3d; sha256 d40d86308faf274af009511bac5e1f84e1dadfde792267d18b8e40ed19d77ff7},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37725629. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: The expression of androgen receptor (AR) is not commonly tested or studied in uterine cancers, unlike estrogen receptor (ER) and progesterone receptor (PR) which are positive in most endometrial carcinomas. In this series, we evaluated the expression of AR and its comparison to ER and PR in different types of endometrial cancers and have reviewed the literature. Materials and methods: The status of AR, ER, and PR expression were evaluated in 71 cases which were categorized into endometrial endometrioid cancer (EEC), non-endometrioid endometrial cancers (NEEC), and metastatic carcinomas of endometrium. Expression of the receptors were compared to each other as well as to mismatch repair proteins (MMR), p53, and body mass index (BMI) using Fisher's Exact test in the StatPlus software. Results: In EECs, the positivity was 97% for all the three receptors. In NEEC, positivity rates were 68%, 48%, and 35% for AR, ER, and PR respectively. In Metastatic carcinomas, AR and ER positivity was seen in 100% while PR was positive in 75% of the cases. In all cancers, the rates were 17% (11/66) for MMR loss, 57% (30/53) for p53 aberrant expression, and 76% (54/71) for the patients with BMI of ≥ 25 (kg/m2). Conclusion: AR is expressed in a high percentage of endometrial cancers. Its significance is more evident in high-grade NEEC where ER and PR may not be expressed. These findings warrant further evaluation of AR expression and candidacy of this pathway as a potential therapeutic target in endometrial cancers.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-09-19).
Identificativi: PMID 37725629 · PMCID PMC10508627 · DOI 10.1371/journal.pone.0291361.
Descrittori MeSH principali: Carcinoma, Endometrioid; Endometrial Neoplasms.
Pagina: https://europepmc.org/article/MED/37725629 — https://doi.org/10.1371/journal.pone.0291361. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:59:26.145Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.